Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
– Agreement to accelerate commercialization of Bylvay™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia – – Albireo to receive upfront payment of $15M and...
-
BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource...
-
– In deutscher Preisliste und allen Apotheken-Softwareprogrammen aufgeführt – – Bylvay ist in den USA, der EU und im Vereinigten Königreich als erste medikamentöse Behandlung für Patienten mit...
-
– Listed on the German national price list and all pharmacy software programs – – Bylvay is approved in U.S., EU and UK as first drug treatment for patients with PFIC – – Only once-daily drug...
-
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement...
-
– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC – – Only once-daily drug indicated to treat all forms of PFIC – – MHRA decision based on data from the largest...
-
– PRV was granted to Albireo with the FDA approval of BylvayTM (odevixibat) in July – – Non-dilutive capital further strengthens the Company’s financial position – BOSTON, Sept. 07, 2021 ...
-
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper,...
-
– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC – – PFIC is a life-threatening liver disease and the number one cause of pediatric liver transplants...
-
– BylvayTM (odevixibat) approved in U.S. & EU as only once-daily drug indicated for patients with PFIC – – Commercialization underway with Bylvay, first prescriptions received in the U.S. – –...